Pembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), according to findings from the KEYNOTE-028 study published online in the Journal of Clinical Oncology
NPC is annually responsible for about 50,000 deaths worldwide. Standard-of-care treatment for recurrent or metastatic disease consists of platinum-containing multiagent chemotherapy, but there are no standard treatment options beyond the first-line setting for patients with platinum-refractory RM-NPC. Furthermore, despite numerous clinical trials, development of new systemic therapies for RM-NPC has stagnated over the past 20 years.
Hsu C, Lee S, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study [published online August 24, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.73.3675.
... to read the full story